About 32 results found for searched term "CDK9-IN-2" (0.104 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M13601 | CDK9-IN-2 | CDK |
| CDK9-IN-2 is a special cyclin-dependent kinase 9 (CDK9) inhibitor, with IC50s of 5 nM and 7 nM in H929 multiple myeloma(MM) cell line (72 hours) and A2058 skin cell line (72 hours), respectively. | ||
| M41435 | CDK9-IN-23 | CDK |
| CDK9-IN-23 is a CDK9 inhibitor with an IC50 of <20 nM. | ||
| M41441 | CDK9-IN-27 | CDK |
| CDK9-IN-27 is a CDK9 inhibitor (IC50s: 0.424 μM). | ||
| M41442 | CDK9-IN-26 | CDK |
| CDK9-IN-26 is a CDK9 inhibitor (IC50=0.18 μM). | ||
| M2434 | BAY 1000394 | CDK |
| Roniciclib | ||
| BAY 1000394 is an orally bioavailable pan-CDK inhibitor for CDK1/2/3/4/7/9 with IC50 of 5-25 nM. It also potently inhibits Aurora A, Clk2, ARK5, FGFR1, Flt3, and JAK2/3. Phase 1/2. | ||
| M2911 | Riviciclib hydrochloride (P276-00) | CDK |
| Riviciclib hydrochloride | ||
| Riviciclib hydrochloride (P276-00) is an effective CDK inhibitor, inhibiting CDK9-CyclinT1, CDK4-cyclin D1, CDK1-Cyclinb with IC50 values of 20 nM, 63 nM, respectively. 79 nM. Riviciclib hydrochloride (P276-00) has anti-tumor activity against Cisplatin resistant cells. | ||
| M4460 | Oroxylin-A | CDK |
| Baicalein 6-methyl ether; 6-Methoxybaicalein | ||
| Oroxylin A is an active flavonoid that inhibits the phosphorylation of MDM2 and SIRT1 through the inhibition of CDK9, thus inhibiting MDM2-mediated degradation of P53 and SIRT1-mediated deacetylation of P53, and ultimately stabilizing the P53 protein.Oroxylin A has strong anticancer activity. | ||
| M5328 | LDC000067 | CDK |
| LDC067 | ||
| LDC000067 is a highly selective CDK9 inhibitor with IC50 of 44 nM, 55/125/210/ >227/ >227-fold selectivity over CDK2/1/4/6/7. | ||
| M6160 | Bohemine | CDK |
| Bohemine is A selective CDK inhibitor with IC50 of 4.6 μM, 83 μM and 2.7 μM against Cdk2/ Cyclin E, Cdk2/ Cyclin A and Cdk9/cyclin T1, respectively. Bohemine also inhibited ERK2, IC50 was 52 μM, and inhibited CDK1, CDK4 and CDK6. Bohemine is also a purine analogue and has a wide range of anticancer activities. | ||
| M9910 | CDKI-73 | CDK |
| CDKI73; Asnuciclib; LS-007 | ||
| Cdki-73 (LS-007) is an orally active and highly effective CDK9 inhibitor with Ki values of 4 nM, 4 nM and 3 nM against CDK9, CDK1 and CDK2, respectively. Cdki-73 down-regulates phosphorylation of RNA polymerase II. Cdki-73 is also an inhibitor of Rab11. | ||
| M10705 | NVP-2 | CDK |
| NVP-2 is an effective and selective ATP competitive cyclin-dependent kinase 9 (CDK9) probe that inhibits CDK9/CycT activity.IC50 The value is 0.514 nM. NVP-2 has inhibitory effects on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases, which IC50 The values are 0.584 μM, 0.706 μM, and 0.605 μM, respectively. NVP-2 induces apoptosis. | ||
| M10707 | FIT-039 | CDK |
| FIT-039 is a selective, ATP-competitive, orally active CDK9 inhibitor against CKD9/cyclin T1 IC50 Is 5.8 μM. FIT-039 does not inhibit other CDKs and other kinases. FIT-039 inhibits HSV-1 (IC50 is 0.69 μM), HSV-2, human adenovirus, and human CMV replication. FIT-039 is a promising antiviral agent that can be used to suppress resistant HSV and other DNA viruses. | ||
| M10734 | YKL-5-124 | CDK |
| YKL-5-124 is a potent, selective, irreversible COVALENT inhibitor of CDK7 and CDK7/Mat1/CycH IC50 53.5 nM and 9.7 nM, respectively. YKL-5-124 is more than 100 times more selective to CDK7 than CDK9 and CDK2 and is inactive to CDK12 and CDK13. YKL-5-124 induces intense cell cycle arrest and inhibits E2F-driven gene expression with little effect on RNA polymerase II phosphorylation status. | ||
| M10843 | KB-0742 dihydrochloride | CDK |
| KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor against CDK9/cyclin T1 IC50 is 6 nM. KB-0742 dihydrochloride is selective for CDK9/cyclin T1, which is more than 50 times more selective than other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity. | ||
| M10879 | RGB-286638 | CDK |
| RGB-286638 is a potent CDK inhibitor that inhibits cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 activity,IC50 1, 2, 3, 4, 5 and 5 nM, respectively, and can inhibit GSK-3β, TAK1, Jak2 and MEK1.IC50 The values are 3, 5, 50, and 54 nM, respectively. | ||
| M10966 | SY-5609 | CDK |
| CDK7-IN-3 | ||
| SY-5609 (CDK7-IN-3) is an orally active, highly selective, noncovalent CDK7 inhibitor with a KD of 0.065 nM. SY-5609 shows poor inhibition on CDK2 (Ki=2600 nM), CDK9 (Ki=960 nM), CDK12 (Ki=870 nM). | ||
| M13596 | Atuveciclib | CDK |
| BAY-1143572 | ||
| Atuveciclib (BAY-1143572) is a potent and highly selective, oral PTEFb/CDK9 inhibitor. Atuveciclib (BAY-1143572) inhibits CDK9/CycT1 with an IC50 of 13 nM. | ||
| M13611 | RGB-286638 free base | CDK |
| RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of 3, 5, 50, and 54 nM. | ||
| M14876 | THAL-SNS-032 | PROTAC |
| THAL-SNS-032 is a selective CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN). | ||
| M20705 | AS2863619 | CDK |
| AS2863619 is a small-molecule cyclin-dependent kinase CDK8/19 inhibitor with IC50 of 0.6099 nM and 4.277 nM, respectively. AS2863619 is a potent Foxp3 inducer in Tconv cells. | ||
| M21148 | (R)-CR8 trihydrochloride | CDK |
| CR8, (R)-Isomer trihydrochloride | ||
| (R)-CR8 trihydrochloride, one of the isomers of CR8, is a potent CDK1/2/5/7/9 inhibitor with anti-proliferative and pro-apoptotic effects on CML cell lines. (R)-CR8 trihydrochloride inhibited CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM ), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). | ||
| M27698 | ABC1183 | GSK-3 |
| ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activities. | ||
| M27766 | (S)-CR8 | CDK |
| (S)-CR8 is the S-isomer of CR8. (S)-CR8 is a potent and selective CDK inhibitor with IC50s of 0.060, 0.080, 0.11, 0.12, and 0.15 μM for CDK2/cyclin E, CDK2/cyclin A, CDK9/cyclin T, CDK5/p25, and CDK1/cyclin B, respectively. (S)-CR8 reduces SH-SY5Y cells survival (IC50 0.40 μM). | ||
| M27775 | BS-194 | CDK |
| BS-194 is an orally active, selective and potent CDK inhibitor. BS-194 inhibits CDK2, CDK1, CDK5, CDK7, CDK9 (IC50s: 3, 30, 30, 250, and 90 nM respectively). BS-194 potently inhibits cancer cells proliferation. BS-194 can be used in the research of cancers like breast cancer, colon cancer. | ||
| M28894 | Samuraciclib | CDK |
| CT7001; ICEC0942 | ||
| Samuraciclib (CT7001) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 µM. Samuraciclib has anti-tumor effects. | ||
| M28917 | CDK8/19-IN-1 | CDK |
| CDK8/19-IN-1 is a potent, selective and oral bioavailable CDK8/19 dual inhibitor, with IC50s of 0.46 nM, 0.99 nM and 270 nM for CDK8, CDK19 and CDK9, respectively. | ||
| M29110 | CDK12-IN-E9 | CDK |
| CDK12-IN-E9 is a potent and selective covalent CDK12 inhibitor and a non-covalent CDK9 inhibitor, while avoiding ABC transporter-mediated efflux. CDK12-IN-E9 has weak binding ability to CDK7/CyclinH complex with an IC50> 1 μM. | ||
| M29539 | FMF-04-159-2 | CDK |
| FMF-04-159-2 is a covalent CDK14 inhibitor. FMF-04-159-2 inhibits CDK14 and CDK2 with IC50s of 39.6 nM and 256 nM in NanoBRET assay, respectively. | ||
| M30106 | NU6102 | CDK |
| NU6102 is a potent CDK1 and CDK2 inhibitor with IC50s of 9.5 nM and 5.4 nM for CDK1/cyclinB and CDK2/cyclinA3, respectively. NU6102 shows selectivity for CDK1/CDK2 over CDK4 (IC50 of 1.6 μM), DYRK1A (IC50 of 0.9 μM), PDK1 (IC50 of 0.8 μM) and ROCKII (IC50 of 0.6 μM). | ||
| M30608 | RGB-286147 | CDK |
| RGB-286147 is a selective and ATP-competitive CDK and CDK-related kinases (CRK) inhibitor with IC50 values ranging from 9-839 nM. RGB-286147 shows less active against other non-CDK/CRK kinases. RGB-286147 induces cell apoptosis, and exhibits anti-tumor activity. | ||
| M31200 | CK7 | CDK |
| CK-7 | ||
| CK7 is a Cdk2/9 inhibitor, which can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367. | ||
| M31276 | PROTAC CDK2/9 Degrader-1 | PROTAC |
| PROTAC CDK2/9 Degrader-1 is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
